-+ 0.00%
-+ 0.00%
-+ 0.00%

Vir Biotechnology's hepatitis delta therapy achieves undetectable virus in all 28 patients completing 96 weeks in Phase 2 trial

PUBT·11/08/2026 21:47:01
Vir Biotechnology's hepatitis delta therapy achieves undetectable virus in all 28 patients completing 96 weeks in Phase 2 trial
  • Vir Biotechnology announced expanded Phase 2 SOLSTICE results showing sustained viral suppression with elebsiran and tobevibart in chronic hepatitis delta.
  • Results presented at AASLD’s The Liver Meeting 2026 showed improved or stable liver stiffness; treatment remained generally well tolerated.
  • Early exploratory findings showed sustained viral suppression following treatment discontinuation, suggesting potential for finite treatment; longer follow-up continues.
  • The pivotal Phase 3 ECLIPSE 1 trial met all study endpoints, supporting a planned US FDA submission in mid-2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261108600446) on November 08, 2026, and is solely responsible for the information contained therein.